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While induced pluripotent stem cells (iPSCs) hold great clinical promise, one hurdle that remains is the existence of a parental
germ-layer memory in reprogrammed cells leading to preferential differentiation fates. While it is problematic for generating cells
vastly different from the reprogrammed cells’ origins, it could be advantageous for the reliable generation of germ-layer specific cell
types for future therapeutic use. Here we use human osteoblast-derived iPSCs (hOB-iPSCs) to generate induced osteoprogenitors
(iOPs). Osteoblasts were successfully reprogrammed and demonstrated by endogenous upregulation of Oct4, Sox2, Nanog, TRA1-81, TRA-16-1, SSEA3, and confirmatory hPSC Scorecard Algorithmic Assessment. The hOB-iPSCs formed embryoid bodies with
cells of ectoderm and mesoderm but have low capacity to form endodermal cells. Differentiation into osteoprogenitors occurred
within only 2–6 days, with a population doubling rate of less than 24 hrs; however, hOB-iPSC derived osteoprogenitors were only
able to form osteogenic and chondrogenic cells but not adipogenic cells. Consistent with this, hOB-iOPs were found to have
higher methylation of PPAR𝛾 but similar levels of methylation on the RUNX2 promoter. These data demonstrate that iPSCs can
be generated from human osteoblasts, but variant methylation patterns affect their differentiation capacities. Therefore, epigenetic
memory can be exploited for efficient generation of clinically relevant quantities of osteoprogenitor cells.

1. Introduction
Current therapies aim to replace autologous grafts with a biomimetic osteoinductive and osteoconductive scaffold coupled with an allogeneic or autologous osteogenic cellular
component [1–3]. This would eliminate complications from
donor site morbidity and promote faster healing and recovery
times for patients. While choices for an osteoinductive and
osteoconductive scaffold are plentiful, choosing a suitable
osteogenic component proves to be more difficult. Mesenchymal stem cells (MSCs) are the current gold standard
as an osteogenic component, as they have the capacity to
differentiate into bone forming cells. Unfortunately, MSCs

numbers shrink with the patient’s age and environmental
factors (e.g., smoking) and MSCs have a limited expansion
capacity in vitro [4–6]. This poses significant challenges for
the production of therapeutic quantities of cells from primary
adult MSCs for osteogenic therapies [7–9]. With the discovery that using four transcription factors can successfully
revert somatic cells back to a pluripotent embryonic state [10–
12], many exciting therapeutic possibilities become available.
iPSCs have the potential to overcome many of the shortcomings of current cell therapy strategies as they can proliferate
infinitely in proper culture conditions making expansion to
large quantities that are readily differentiated into cells such
as MSCs and osteoprogenitors [13–16]. Another advantage of
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iPSCs is their ability to be used both in banks of HLA
matched allogeneic cells [17–19] and autologously to generate
therapeutic cells. Thus, iPSCs generated from donor cells
using nonintegrative technologies (mRNA, Sendai, Episomal,
etc.) could be a promising source of osteogenic cells [20–
23]. However, an important topic still to be deciphered is
variations seen during the iPSC reprogramming process that
result in reduced, misdirected, or preferential differentiation capacity [15, 23–30]. Previous studies have found that
a cause for some of these preferential differentiations is
the remaining lineage-specific epigenetic (histone or DNA
methylation mediated) profile of the iPSC, facilitating the
cells differentiation capacity to favor the originating parental
cell’s germ-layer lineage [23, 28–32]. While previous studies
have focused on the elimination of all residual epigenetic
signatures, we propose here to take advantage of this parental
cell memory as a means to preferentially enrich and expand a
cell population of interest. Thus, reprogramming would provide an intermediate pluripotent master cell bank capable of
limitless expansion of cells that are more readily differentiated
back into their original cell type. The idea of a lineage-specific
iPSC bank of cells for differentiation into the origin cell type,
as compared to banks of multilineage capable iPSCs, would
increase the likelihood of a successful differentiation and also
reduce (but not eliminate) the burden of screening for fully
reprogrammed cells [28, 30, 31].
Here we wished to determine if primary human osteoblasts are a valuable cell type for reprogramming and differentiation in comparison to adult human fibroblasts (hFB).
While previous studies have examined the ability of various
cell types including MSCs to be reprogrammed, it has yet
to be determined if primary osteoblasts can be induced into
a pluripotent state [14–16, 24, 27, 33]. As a source for the
reprogramming process, osteoblasts provide a homogenous
initial cell population as they are easily isolated from dense
bone tissue from deceased donors after the loose bone
marrow MSCs and hematopoietic cells are washed away.
We further coupled the Taqman hPSC Scorecard analysis
and the embryoid body (EB) differentiating technique to
analyze the differentiation capacity of these iPSCs [22, 24,
34]. Using methylation analysis we discovered variations
in methylated genes compared to other mesodermal origin
iPSCs demonstrating an epigenetic pattern that could be used
to identify mesodermal somatic memory effects. We further
deciphered the capacity of these germ-layer memory affected
cells to differentiate into osteoprogenitors without the ability
to form adipocytes, for large-scale therapeutic productions.
These data indicate that while these cells are epigenetically
imprinted from their parental origins, their capacity to form
osteogenic cells is unaffected.

2. Materials and Methods
2.1. Cell Culture. Human osteoblasts (hOB) were isolated
from iliac crest bone tissue of 11 research-authorized donors
from LifeNet Health (Virginia Beach, VA), The donor cells
used for these experiments were consented and authorized
for use in research purposes. All donors undergo rigorous
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screening of health history and infectious and genetic disorders prior to cell extraction. To extract cells, the bone was
broken up and the marrow components were eliminated with
washes and centrifugation. The remaining bone chips were
then placed in growth media composed of DMEM with glutamine (Thermofisher), 10% FBS (Gibco), and 1% antibioticantimycotic (ABAM) (Sigma) to expand the osteoblasts. After
isolation from the bone chips, hOBs were maintained in the
media for 10–15 days without passaging (passage 0) before
qRT-PCR analysis and passaging onto separate culture plates
for calcium deposition assays. iPSCs were cultured on MEF
(Globalstem) in KO-SR media (Thermofisher) or on Geltrex
(Thermofisher) in mTeSR1 media (Stem Cell Technologies).
hMSCs (Lonza) were cultured on CellStart CTS (Gibco) in
StemPro MSC SFM Xenofree (Gibco) or standard growth
media. Normal human osteoblasts (NHOst, Lonza) were
grown in manufactures recommended media (Clonetics
OGM Osteoblast Growth Medium, Lonza). For expansion
experiments all cells were passed in log-phase of growth
(∼75–80% confluent), counted during passaging using a
hemocytometer, and replated at 10 × 105 .
2.2. iPSC Reprogramming. hOBs (Passage 2) were reprogrammed as described in CytoTune-iPS Reprogramming Kit
manual (Thermofisher). Briefly 2 × 105 osteoblasts were
infected with reprogramming cocktail at a multiplicity of
infection (MOI) of 3 for 24 hours. After 7 days culture in
culture media, the cells were passed onto MEFs and cultured
in KOSR media for approximately 14–28 days until colonies
emerged. Individual colonies were selected based on TRA1-81 staining, expanded, and fully characterized before use.
Reprogramming efficiencies were calculated by dividing successfully TRA-1-81 (Stemgent) staining colonies by the total
number of cells plated onto final MEF feeder layers. Before
use in experiments, iPSCs were passaged with Accutase
(Stem Cell Technologies) onto Geltrex (Thermofisher) and
maintained in mTeSR1 media for two passages.
2.3. Embryoid Body Differentiation. As previously described
[13, 23, 24], hOB-iPSCs were exposed to dispase, at 37∘ C for
7 minutes, placed onto nonadherent dishes, and cultured for
7 days in EB media containing DMEM with Glutamax, 15%
FBS, and 1% ABAM to allow EB aggregate formation. After 7
days in culture, EBs were seeded onto dishes with 0.1% gelatin
and cultured for 7 subsequent days in EB media.
2.4. Osteoprogenitor Differentiation of iPSC. iPSCs were passaged using Accutase into single cell suspension and plated
onto Geltrex coated plates in 20% Knock-out serum replacement media. Twenty-four hours following successful plating, the media was changed to DMEM/F12 with Glutamax
supplemented with 20% FBS and 1% ABAM. Cells were
allowed to grow with media replacement every third day for
7 days and passaged 1 : 4 until a uniform mesenchymal-like
morphology was observed (3–5 passages). These cells were
then subcultured in DMEM, 10% FBS, and 1% ABAM until
use in further experiments.
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2.5. Osteogenic, Adipogenic, and Chondrogenic Differentiation. OBs, iOPs and hMSCs were cultured with osteogenic
differentiation media containing DMEM, 10% FBS, 1%
ABAM, 50 𝜇M Ascorbate-2-Phosphate (Sigma), and 10 mM
𝛽-glycerophosphate (Sigma) for 21 days with media changes
every 2 days. For adipose differentiation, the cells were
cultured with adipogenic media containing DMEM, 10% FBS,
1 𝜇M dexamethasone, 1 𝜇M indomethacin, 200 𝜇M isobutyl1-methylxanthine, and 10 𝜇g/mL insulin for 14 days with
media changes every 2 days. For chondrogenic differentiation, the cells were passaged and counted, and 4 × 105 cells
were centrifuged at 300 ×g for 5 min in a 1 mL v-bottom tube.
Resulting pellets were carefully resuspended in chondrogenic
differentiation media (StemPro Chondrogenesis Differentiation Kit, Life Technologies) and allowed to differentiate for
14 days with media changes every 2 days.
For Alizarin Red S (Sigma) staining, cultures were fixed
with 10% formalin for 10 minutes and then washed with
1x PBS. The cells were then incubated with the Alizarin
Red solution for 2 minutes and then rinsed with distilled
water and covered in 1x PBS for imaging. For Oil Red O
staining of lipids, differentiation wells were fixed with 10%
formalin for 10 minutes, rinsed with PBS, and stained with Oil
Red O solution (Sigma) for 10 minutes. The cells were then
washed with distilled water and imaged. For chondrocyte
HC staining, the fixed cell pellets were embedded in paraffin
and sectioned. The sections were first cleared of paraffin
using xylene and rehydrated in gradients of alcohol and
then stained with Alcian blue (Sigma) in 3% acetic acid;
the sections were then stained with Alcian blue and then
dehydrated with 95% ethyl alcohol, 100% ethyl alcohol, and
xylene. The slides were then mounted and imaged.
2.6. qRT-PCR and Scorecard Analysis. Trizol (Thermofisher)
digestion was used to extract RNA from the desired cells
according to manufacturer’s instruction. The purified mRNA
was transcribed to cDNA with the RNA-to-cDNA kit
(Thermofisher). All qPCR was performed with Taq-man
probes (Thermofisher, Sox 2; Hs01053049 s1, Oct4 (POU5F1);
Hs00999634 gH, NANOG; Hs04260366 g1, hTERT;
Hs00972656 m1, BMP7; Hs00233476 m1, Actin A2;
Hs00426835 g1, PPAR𝛾; Hs01115513 m1, LEP; Hs00174877
m1, LPL; Hs00173425 m1, ADIPOQ; Hs00605917 m1, osteocalcin (BGLAP); Hs01587814 g1, Osteopontin (GZMB);
RUNX2;
Hs00231692 m1,
BMP4;
Hs01554355 m1,
COMP;
Hs00164359 m1,
ACAN;
Hs03676628 s1,
Hs00153936 m1, COL10A1; Hs00166657 m1, Sendai Virus
Detection; Mr04269876 mr, Mr04269878 mr, Mr04269879
mr, Mr04269880 mr, and Mr04269881 mr). To determine
differences in iPSC pluripotency and EB differentiation capacity, we used the Thermofisher’s Taqman hPSC Scorecard Panel array. The array derives an algorithmic comparison of input pluripotent and EB differentiated iPSCs to its
reference set of data that is comprised of the methylation
status of genes and their expression levels found in (differentiated/undifferentiated) 20 ESC and 12 iPSC. Statistical
significance was analyzed with a Student 𝑇-test or a one-way
ANOVA with TUKEY post hoc test where appropriate.
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2.7. Flow Cytometry. The cells were detached from culture
plate with Accutase (Thermofisher) and 0.5–1 × 106 cells/
100 𝜇L were suspended in flow cytometry buffer (PBS, 3%
FBS, 1% sodium azide). The cells were incubated with fluorescently conjugated antibodies for 1 hr at room temperature. Antibodies against TRA-1-81 (0.25 𝜇g/106 cells; Stem
Gent), TRA-1-60 (0.25 𝜇g/106 cells; StemGent), and SSEA4
(1 𝜇g/106 cells; Santa Cruz Biotechnology) were used. The
hMSCs and iOPs were probed with antibodies to CD29
(10 𝜇g/mL; CALTAG), CD14 (5 𝜇g/mL, Thermofisher),
CD166 (5 𝜇g/mL, Thermofisher), CD105 (5 𝜇g/mL, Thermofisher), CD90 (5 𝜇g/mL, eBioscience), CD44 (0.15 𝜇g/
106 cells; Thermofisher), CD45 (10 𝜇g/106 cells; R&D Systems), and CD31 (4 𝜇L/106 cells; Thermofisher). Unconjugated primary antibodies for SSEA4 and CD34 were
detected with an APC-conjugated secondary antibody goat
(Gt), anti-Ms IgG (5 𝜇g/mL; Thermofisher). The cells were
assayed with the BD Accuri C6 flow cytometer. Isotype
control antibody groups and unstained cells were used to
gate the positive cells and ensure that the fluorescent
compensation was correct.
2.8. Immunofluorescence and Alkaline Phosphatase Staining.
Live iPSCs were labeled with TRA-1-60 and TRA-1-81 antibodies (1 : 100; StemGent) in mTeSR1 media following manufacturer’s instructions and imaged with Zeiss Axio Observer
Z1 microscope (see flow cytometry methods for antibody
information). Briefly, the mTeSR1 media were removed and
replaced with fresh media containing the TRA-1-60 or TRA1-81 antibody. The cells were incubated for 30 minutes in
the dark and washed twice with PBS, and then the mTeSR1
media were replaced. For alkaline phosphatase staining, iPSC
colonies were fixed with 10% formalin and labeled with
alkaline phosphatase (Fast Red Violet) staining kit (Stemgent)
following manufacturer’s instruction. Briefly the colonies
were washed with PBS and Tween 20, and then incubated
with the alkaline phosphatase substrate staining solution for
15 minutes. The solution was then removed and the colonies
were washed with PBS twice before imaging with a camera.
Cells were fixed with 10% formalin (Sigma) for 10 minutes
and washed with PBS. For IF staining, the cells were labeled
with primary antibodies: mouse anti-Sox2 (1 : 100; Cell Signaling), mouse anti-Oct4 (1 : 100; Cell Signaling), mouse anti𝛽-III tubulin (5 𝜇g/mL; Abcam), mouse anti-SMA (1 : 100;
Abcam), and mouse anti-AFP (5 𝜇g/mL; Abcam). Secondary
antibodies, Donkey anti-mouse IgG TRITC conjugated antibody (1 : 1000; Abcam) and goat anti-mouse IgG-FITC conjugated antibody (1 : 1000; Abcam), were used and DAPI stain
(Thermofisher) was used to label the cell nuclei.
2.9. Genomic DNA Methylation Detection. Cells were collected and subjected to Trizol genomic DNA extraction
following the supplied protocol (ThermoFisher Scientific).
Subsequently, the collected genomic DNA was used to perform a methylation sensitive enzymatic digestion (EpiTect
Methyl II DNA Restriction Kit) followed by PCR using
primers specific to the promoter/gene regions of interest (SA
Bioscience). Following PCR amplification the Ct values were
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input into the SA Bioscience calculation and quality control
spreadsheet for analysis. Ct differences of more than 3 from
internal control digestions were excluded from analysis.

3. Results
3.1. Osteoblast Characterization. To extract primary human
osteoblasts, bone chips from 11 donors were washed and processed thoroughly to remove all bone marrow constituents
and then the chips were placed in culture dishes with growth
media, which allowed for human osteoblasts (hOBs) to
migrate out (Figure 1(a)). To confirm the identity of the
donor-derived osteoblasts, cells were exposed to osteogenic
media to induce calcium secretion and deposition. Alizarin
Red S staining confirmed that cells grown in osteogenic
media produced calcium deposition while cells cultured in
nonosteogenic growth media did not (Figures 1(b) and 1(c)).
To further confirm that our extraction process was isolating
osteoblast populations, we examined the expression of a set of
osteoblast specific genes. All 11 of our isolated hOBs showed
significantly increased expression of osteopontin (𝑃 = 0.017)
and BMP2 (𝑃 < 0.01) and similar levels of expression of
RUNX2, collagen 1 A1, and osteocalcin as compared to the
commercially available normal human osteoblast (NHOst)
line (Figure 1(d)), indicating that our isolation procedure was
successful.
3.2. Osteoblast Reprogramming. As many primary cell types
are difficult to reprogram and some correlations have been
established between initial pluripotency gene expression and
reprogramming efficiency [24, 27], we examined the gene
expression levels of Sox2 and Oct4 in our isolated hOBs.
This revealed that the hOB cells had a significant increase of
Sox2 and Oct4 gene expression as compared to the commonly
reprogrammed BJ fibroblast cell line (Figure 1(e)), possibly
indicating hOBs have a favorable reprogramming expression
profile.
In order to reprogram hOB into an iPSC state, the cells
were exposed to Sendai virus, in standard culture media,
expressing the reprogramming factors (c-Myc, Sox2, Oct4,
and Klf4). The cells were then cultured for 7 days before being
passaged onto an inactivated mouse embryonic fibroblast
(MEF) feeder layer. Successful reprogramming at the end
of 4 weeks was determined based upon initial observation
of a cellular conversion to a high nuclear to cytoplasmic
ratio, colony formation with a well-defined border, and
TRA-1-81 expression and subsequently by an initial alkaline
phosphatase staining (Figures 1(f) and 1(g)). The total number
of successfully reprogrammed initial colonies was counted
prior to picking and the overall efficiency was calculated to be
0.1% for the hOBs, which was similar to the reprogramming
efficiency obtained with fibroblasts at 0.13%. The selected
hOB derived iPSCs (hOB-iPSCs) were further propagated on
MEFs and frozen at various time points while being continuously screened during expansion for TRA-1-81 expression,
indicating continued maintenance of pluripotency.
3.3. hOB-iPSC Characterization. The hOB-iPSCs were then
assayed for endogenous pluripotent gene expression of Sox2,
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Oct4, and Nanog (Figure 2(a)). The hOB-iPSCs had a significant increase in expression over the parental hOBs, with
an approximate 1,000-fold increase in Sox2 expression (𝑃 <
0.001, ANOVA), 100-fold increase in Oct4 expression (𝑃 <
0.001, ANOVA), 10,000-fold increase in Nanog expression
(𝑃 < 0.001, ANOVA), and 100-fold increase in hTERT
expression (𝑃 < 0.001, ANOVA). To further confirm the
protein expression the iPSCs were labeled with antibodies
against Sox2, Oct4, Nanog, and TRA-1-60, which revealed
high expression of all pluripotency associated markers (Figure 2(b)). To determine if there was residual Sendai virus
gene expression in the reprogrammed cells, we performed
a Sendai-gene specific qRT-PCR. As expected we saw no
expression in all of our reprogrammed cell lines (data not
shown).
3.4. hOB-iPSC Differentiation Capacity. To determine the
differentiation propensity of the iPSCs for certain germlayer lineages, the cells were analyzed with the Taqman
hPSC Scorecard panel (Thermofisher). The Scorecard panel
uses a robust algorithm based on the comparative methylation status, gene expression, and related differentiation
propensity of 12 different iPSC lines, 20 ESC, and their
differentiated progeny [34, 35]. The Scorecard panel initially
examines the gene expression of undifferentiated and EB
differentiated iPSCs for certain pluripotent (CXCL5, Nanog,
Pouf51, Sox2, etc.), ectodermal (DRD4, PAX3, Sox1, Wnt1,
etc.), mesodermal (HAND1, ESM1, BMP2, ODAM, etc.), and
endodermal (FoxA2, GATA4, HNF1B, Sox17, etc.) markers.
Then by inputting these values into an algorithmic assessment
system, the expression data is assigned a score based on the
comparisons to internal standards (established ESC and iPSC
lines). Our analysis revealed that both hOB-iPSCs and hFBiPSCs were pluripotent based on consistent algorithm scores.
When differentiated into EBs, the EB hOB-iPSCs cells showed
significantly (𝑃 < 0.05) increased algorithm scores associated
with the ectodermal and mesodermal lineages, but not for
endoderm (Table 1). This was in contrast to the hFB-iPSC EB
cells, which scored positive for all three germ layers.
Using immunocytochemistry we then confirmed the
trilineage capacity of our hOB-iPSCs by examining the EBs
expression of germ-layer associated cytoplasmic markers, 𝛽III tubulin (ectoderm), Alpha Fetoprotein (AFP, endoderm),
and smooth muscle actin (SMA, mesoderm) (Figure 3(a)).
We successfully detected the presence of all three of these
markers confirming these cells could make endodermal cells.
However, we next stained for germ-layer specific transcription factors and identified strong staining for HAND1 (mesodermal) and Sox1 (ectodermal) but extremely low levels of
the endodermal marker Sox17 (Figure 3(b)). Finally, to ensure
we did not have any remaining pluripotent cells we also
stained for the presence of TRA-1-61, which was undetectable
(Figure 3(b)). These data aligned with our algorithm analysis
indicate these cells lack complete differentiation capacity into
the endodermal lineage.
3.5. Induced Osteoprogenitor Derivation. In order to take
advantage of the potential “parental cell memory” of these
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Figure 1: Characterization and reprogramming of donor-derived osteoblasts. (a) Example of donor bone chip in media (arrow) with
osteoblasts emerging onto culture flask (asterisk). Osteoblasts were cultured in growth (b) or osteogenic induction media (c) and the
resulting calcium deposits were stained with Alizarin Red S and imaged (scale bars = 30 𝜇m and inserts are at 1x). (d) The donor-derived
osteoblasts were assayed with qRT-PCR for osteoblast markers, osteocalcin, osteopontin, RUNX2, BMP2, and COL1A1 and compared to
a commercially available osteoblast cell line (NHOst). (e) qRT-PCR analysis of pluripotent gene expression, Sox2 and Oct4, in the hOBs
compared to neonatal BJ fibroblasts. (∗ 𝑃 < 0.05). (f) Alkaline phosphatase staining of primary reprogramming plate of hOB-iPSC. (g) TRA1-81 immunofluorescence of initial hOB-iPSC colony (scale bars = 30 𝜇m).

hOB-iPSCs, we further investigated the capacity of hOBiPSC to form mesodermal origin osteoprogenitors (iOPs)
cells. To accomplish this the hOB-iPSCs were differentiated
using previously established differentiation protocols [36–
38], using a single cell monolayer of iPSC cultured on

0.1% gelatin plates with serum-containing media, described
here as induced osteoprogenitors (iOPs). Following two
passages in progenitor growth media a consistent population of spindle-shaped mesenchymal cells emerged. Flow
cytometry was conducted to determine if they exhibited the
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Figure 2: Pluripotent marker expression analysis of hOB-iPSCs and hFB-iPSCs. (a) hOB-iPSC and hFB-iPSC qRT-PCR expression of
endogenous pluripotent genes, Sox2, Oct4, Nanog, and hTERT (∗ 𝑃 < 0.01). (b) Immunofluorescence of hOB-iPSC for pluripotency markers,
TRA-1-60, Oct4, Nanog, Sox2, and IgG-FITC control (scale bars = 30 𝜇m). (∗ indicates nonstaining MEF background.)

Table 1: Scorecard analysis of induced pluripotent stem cells.

hOB-iPSC
hOB-EB
hFB-iPSC
hFB-EB

Passage

Pluripotent
score

Ectodermal
score

Mesodermal
score

Endodermal
score

14
10
26
20

−0.03
−0.77
−0.56
−2.14

−0.50
2.51
−0.12
6.10

0.00
2.60
0.74
3.62

−0.42
0.46
0.26
1.32

Bold: significantly downregulated; italic: significantly upregulated; normal font: not different from internal algorithm reference iPSC/ESC expression.
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Figure 3: Differentiation of hOB-iPSCs into trilineages. (a) hOB-iPSC embryoid bodies (EBs) labeled with antibodies for cytoplasmic germlayer markers, 𝛽-III tubulin (𝛽-III; ectoderm), AFP (endoderm), and SMA (mesoderm). (b) hOB-iPSC EBs labeled with antibodies for germlayer transcription factors, HAND1 (mesoderm), Sox1 (ectoderm), and Sox17 (endoderm). (c) Undetectable staining for pluripotent cells with
TRA-1-60. Scale bars = 40 𝜇m.

well-characterized cell surface protein markers indicative of
cells of mesenchymal lineages (Figure 4(a)) [39–42]. The
cells were positive for all mesenchymal-associated markers
(CD90, CD105, CD166, CD44, and CD29) and negative for
hematopoietic/endothelial cell markers, (CD14, CD45, and
CD31) proving we had successfully generated iOPs.
As it is important for therapeutic purposes to be able
to expand these cells to therapeutic quantities, we next
examined the iOPs growth and propagation characteristics.

Their doubling rate was found to be less than 24 hours, almost
triple that of the hMSCs even when grown with higher FBS
concentrations or in defined xenofree media. This high rate
of growth would allow for these cells to be grown to over a
1000-fold increase in less than 10 days (Figure 4(b)), making
them an easily scalable cell line.
To next determine the time necessary to see the emergence of a differentiated iOP population, the hOB-iPSCs and
hFB-iPSCs were differentiated into iOPs and sampled at days
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Figure 4: Induced osteoprogenitors (iOPs) cells differentiated from hOB-iPSC. (a) Flow cytometry analysis of iOPs and hMSCs revealed that
the cells were positive for mesenchymal markers (CD29, CD44, CD90, CD105, and CD166) and negative for hematopoietic markers (CD14,
CD31, and CD45) (black: CD marker expression, red: isotype control, and blue: unstained control). (b) Significantly (𝑃 < 0.05) faster growth
kinetics of the hOB-iOPs and hFB-iOPs, as compared to hOBs and hMSCs in either 20% serum-containing media or Xenofree StemPro media
at all time points. (c) Differentiation time of hOB-iPSCs to iOPs was assayed using flow cytometry for mesenchymal cell markers, CD44 and
CD105. (d) iOPs were found to have similar levels of osteogenic related genes, RUNX2, BMP2, osteocalcin, and COL1A1 as compared to
hMSCs ∗ indicates significant difference from the hOB-iOPs (𝑃 < 0.05). iOPs downregulated all pluripotency genes, Oct4, Sox2, Nanog, and
hTERT indicating successful differentiations. ∗ indicates significant difference from the iPSC (𝑃 < 0.05).

0, 2, 4, and 6 of the protocol. By day 2 of the differentiation,
approximately 80% of the hOB-iPSC differentiating cells
and 60% of the hFB-iPSC differentiating cells had begun to
express the mesenchymal markers CD44, and 60% of both
lines expressed CD105 (Figure 4(c)), suggesting they had
differentiated into iOPs. The cells were then analyzed for
gene expression of osteogenic associated markers (BMP2,
osteocalcin, COL1A1, and RUNX2), which were found to
be significantly upregulated in the iOP population with
only BGLAP found to be significantly different as compared
between the iOP and hMSC population (Figure 4(d)). As
contaminating pluripotent cells pose a significant issue for
deriving therapeutic cell populations we next assayed the cells
for pluripotent markers Nanog, Sox2, Oct4, and hTERT. The
iOPs showed a significant downregulation of all pluripotent
genes back to levels comparable to the hMSCs indicating a
lack of pluripotent cells in our differentiated populations.

As previous studies have noted that the generation of
MSCs from iPSCs sometimes yields cells with only the
capacity to generate chondrocytes and osteoblasts [38], we
aimed here to explore if the germ-layer preferences we noted
could possibly explain some of their findings. In order to
examine the multipotency of the hOB-iOP population, we
analyzed their osteogenic, chondrogenic, and adipogenic
differentiation capacity. Following these differentiations the
hMSCs and the hFB-iOPs had a significantly more adipocyterelated gene expression as compared to the hOB-iOP population (Figure 5(a)), while both the hMSCs and iOPs had
similar levels of osteogenic and chondrogenic gene expression (Figure 5(b)). The differentiated iOPs and hMSCs were
then stained for osteogenic calcium deposits with Alizarin
Red S and adipogenic lipid droplets with Oil Red O and
for chondrogenic glycosaminoglycans with Alcian blue (Figure 5(b)). This revealed that both hOB-iOPs and hFB-iOPs

Relative gene expression

Stem Cells International
107
106
105
104
103
102
101
100

11

Adipogenic differentiation
∗

∗
hOB-iOP

∗

∗

hFB-iOP

PPAR𝛾
LEP

∗

∗

hMSC
LPL
ADIPOQ

∗

102

Osteogenic differentiation

101

∗

100
10−1

∗
hOB-iOP

hFB-iOP

RUNX2
BMP2

hMSC

105
104
103
102
101
100

Osteopontin
Osteocalcin

Chondrogenic differentiation
∗ ∗

∗
∗

hOB-iOP
Sox9
COMP

hFB-iOP

hMSC
COL10A1
ACAN

(a)

Adipogenic media

Osteogenic media

Chondrogenic media

hMSC

hFB iOP

hOP iOP

Growth media

(b)

Figure 5: iOP differentiation to adipocytes, chondrocytes, and osteoblasts. (a) Gene expression of adipocyte, chondrocyte, and osteoblast
markers normalized to their respective growth media control cells expression levels. Adipogenic expression levels were lower than both hFBiOP and hMSC indicating a lack of adipogenic capacity ∗ Significantly different from hOB-iOP differentiated cells (𝑃 < 0.05). (b) Alizarin
Red S, Oil Red O, and Alcian blue staining of adipogenic, osteogenic, and chondrogenic differentiations with a hematoxylin counterstain
demonstrated comparable chondrogenic and osteogenic differentiation capacity, with a lack of hOB-iOP adipogenesis. Scale bars = 30 𝜇m.

had similar amounts of Alizarin Red S staining compared
to the hMSCs after 21 days (Figure 5(b)). The Oil Red O
staining of the adipose differentiations showed the hMSC and
hFB-iOPs with lipid vacuoles, while the hOB-iOPs showed
undetectable staining (Figure 5(b)). The Alcian blue staining
of our chondrogenic differentiations showed equal staining
amongst the different cell groups. These data demonstrate
that our hOB-iOPs could only differentiate into osteogenic
and chondrogenic cell types, indicating that the original
germ-layer deficiencies we found in these cells impacted their
downstream capacity.
We next wished to determine if our hOB-iPSC harbored some epigenetic variation that may be associated
with their somatic origins that could be a causative factor in the preferential ectoderm/mesodermal differentiation preferences, which would also explain the lack of

adipocyte differentiation capacity we were witnessing. To test
this we preformed methylation sensitive qPCR for several
gene promoters involved in fate determination for endoderm (FOXA2, STAT1), ectoderm (OLIG2), and mesoderm
(NOTCH2, GATA2, PPAR𝛾, RUNX1, and RUNX2). Interestingly, we found a significant variation in the amount of
methylation between the hFB and the hOBs at all stages
of reprogramming and differentiation (Figure 6). Interestingly, NOTCH2, a key negative regulator of osteogenesis
[43, 44], was significantly methylated in the hFB-iOPs as
compared to the hOB-iOPs, while RUNX2 was methylated
at similar levels at this stage (Figure 6(c)). Similarly, PPAR𝛾,
a key regulator of adipogenesis [45], was significantly more
methylated in hOB as compared to the hFB, both before
reprogramming and after differentiation into iOPs (Figures
6(a) and 6(c)). Interestingly, the RUNX2 gene in hOBs had
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Figure 6: Promoter methylation analysis for unreprogrammed, parental iPSC, and iOP cells. Methylation sensitive enzymatic digestions were
performed for hFB and hOB (a), hFB-iPSC and hOB-iPSC (b), and hFB-iOP and hOB-iOP (c). Graphs indicate promoter percent methylated
(black) versus percent unmethylated (gray) of a subset of genes: endoderm (FOXA2, STAT1), ectoderm (OLIG2), and mesoderm (NOTCH2,
GATA2, PPAR𝛾, RUNX1, and RUNX2).

a higher percentage methylation than in the hFBs, contrary
to what would originally be assumed (Figure 6(a)). These
data together indicate the hOB-iOPs capacity to form both
osteogenic and chondrogenic cells, but not adipocytes, which
are likely due to the differential epigenetic regulation of these
genes. The vast methylation differences between the hOB
and hFBs and similar contrasts at the iPSC stage could also
indicate a regulatory variation in the methylation on a more
global scale during the reprogramming process.

4. Discussion
Previous iPSC reprogramming studies have used many different cell types including mesenchymal stem cells; however,
to our knowledge, no other study has used osteoblasts
to generate iPSCs. We show that osteoblasts are capable of being reprogrammed and do so at rates similar
to BJ fibroblast cells, an unusual feature for a primary
cell type, that typically are much more difficult to reprogram [24, 27]. One possible mechanism behind the hOB’s
reprogramming efficiency is the relatively elevated basal
expression of the pluripotent master regulatory genes Oct4
and Sox2 in these cells. As previous studies have found
that elevated expression of Oct4 can generate a primed
state during reprogramming [46–48], here we demonstrated that the hOB-iPSCs were successfully reprogrammed
as evident from both their morphological shifts coupled
with endogenous expression of OCT4, SOX2, and Nanog
and the cell surface markers TRA-1-81 and TRA-1-60.
However, the differentiation capacity of these cells seemed to
favor the mesodermal and ectodermal lineages. This finding

indicated that the cells likely harbored some epigenetic
memory that generated these preferential differentiation
features as has been previously reported in the literature
[23, 25, 26, 31]. Subsequently, when we analyzed the methylation status of several gene promoters important in fate
specification, we found vast differences in the methylation
patterning between the hFB and the hOB at all stages.
These variations coupled with the algorithm scores, gene
expression, and differentiation capacity indicate the cells are
likely subject to some misappropriated epigenetic changes
during the reprogramming process. Interestingly, we had
noted while in active culture that the hOB-iPSCs had a
tendency to spontaneously differentiate into mesenchymallike cells, which had a very high rate of division. This supports the notion others have reported describing epigenetic
variations that cause iPSCs to differentiate more easily into
the same developmental lineage as the parental cells [23, 25,
26, 31]. While we showed that hOB-iPSCs differentiate as
readily as hFB-iPSCs into iOPs, the cells lacked the ability
to form adipocytes, similar to previous reports [38]. When
we analyzed the methylation state of mesodermal fate control
genes, we confirmed that the state of the adipose regulatory
gene PPAR𝛾 and the negative regulator of osteoblastogenesis
NOTCH2 were methylated in hOB-iOPs, explaining the lack
of adipogenesis. However, we unexpectedly found RUNX2
regulatory regions methylated at higher percentages than
we were expecting in the parental hOB, possibly due to
culture adapted, noncalcium producing state they are kept
in during propagation. It has also been demonstrated that
hyper- and hypomethylated regions within promoters have
been shown to both negatively and positively regulate gene
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expression depending on the sites methylated. Thus, next
step experiments should analyze site-specific methylation to
determine if this is an issue. Furthermore, these patterns
could indicate a general methylation difference on a more
global scale impacting gene expression. These preferential
differentiation tendencies of iPSCs are typically viewed
negatively as the gold standard pluripotent cells, ESCs,
lack epigenetic memory. However, lineage-specific epigenetic
retention can be advantageous if it is able to generate cell
types of parental origin without necessitating the addition of
stimulating factors. By exploiting the tendency of hOB-iPSCs
to revert back towards osteoprogenitor cells with high rates of
proliferation, without the capacity to form adipocytes, large
quantities of osteogenic cells can be produced using master
banks of germ-layer specific iPSCs. As these iPSCs could
be reprogrammed using the nonmutagenic, nonintegrative
techniques demonstrated here, the induction genes would
no longer be present following their successful generation,
eliminating their possible contribution to future tumorgenesis. Further, the high rate of division we witnessed is similar
to others who have noted that the default state of cells at
any stage of development, but especially of those at a more
primordial state, is to proliferate [49, 50]. Indeed, upon isolation into 2D culture, most nonproliferative cells will begin to
divide without any cancer causing mutations being present
[51] and without telomerase expression exhibiting a finite
lifespan [9]. Thus, with careful screening the proliferation
would be almost invariably viewed as a positive aspect of
these cells, without any concern for unusually high rates of
somatic mutations and thus tumorigenic cells. These cells
can then be utilized alone, or with biological matrices and
devices to further healing treatments. While choices for an
osteoinductive and osteoconductive scaffold are plentiful,
choosing a suitable osteogenic component proves to be more
difficult. While MSCs, the current gold standard for bone cell
therapies, have the capacity to differentiate into osteogenic
cells, they also have the capacity to form adipocytes, unlike
the osteoprogenitors presented here. Thus, having a more
lineage-committed progenitor could lead to a quicker, more
direct contribution to the regenerating bone with less off
target differentiation. In future studies it will be important
to determine if our findings are representative of a random
reprogramming fault or if there is a specific recurrence of
these markings within osteoblast populations, which could
vary based upon the location they are isolated from. Furthermore, by expanding these studies to determine which
cells have a predisposition to a certain lineage or cell type,
incorporation of cells into biological and synthetic scaffolds
may become simpler and require fewer manipulations to push
the cells to the final cell type. Once these types of residual
epigenetic marks have been vetted in in vivo applications
as harmless, this strategy would ease the transition of these
technologies into the clinic by simplifying differentiation
procedures and the characterization of pluripotent cells.
Regardless, if screening of cells is required, the methylation
patterns here could suffice as a means to identify truly multipotent mesenchymal cells derived from iPSCs, adding to our
bulk of knowledge about these variant germ-layer epigenetic
profiles.
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5. Conclusion
These studies for the first time reveal that human osteoblasts
are capable of being reprogrammed back to a pluripotent
state. Furthermore, these hOB-iPSCs harbored DNA methylation variants that resulted in restricted lineage capacity. While hOB-iPSC generated osteoprogenitors expanded
rapidly, they were only capable of generating osteogenic and
chondrogenic cells, lacking the ability to form adipocytes. If
used therapeutically for cartilage or bone repair, this would
eliminate the possibility of misdirected differentiation into
fat. Together the data presented here demonstrates that the
epigenetic memory effect found in reprogrammed hOBs
could be used to advantageously generate an osteoprogenitor
cell population with a more lineage-committed state for
future therapeutic use.
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